title: Re: "Confounding by indication and channeling over time: the risks of beta2-agonists".
authors.forename: N
authors.initials: N
authors.lastname: Pearce
authors.forename: R
authors.initials: R
authors.lastname: Beasley
authors.forename: J
authors.initials: J
authors.lastname: Crane
authors.forename: C
authors.initials: C
authors.lastname: Burgess
mesh_terms: D000318:Adrenergic beta-Agonists / Q000009:adverse effects* / Q000600:supply & distribution; D000420:Albuterol / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality; D016022:Case-Control Studies; D015331:Cohort Studies; D015986:Confounding Factors, Epidemiologic; D015340:Epidemiologic Research Design; D005280:Fenoterol / Q000009:adverse effects* / Q000600:supply & distribution; D006801:Humans; D016013:Likelihood Functions; D009520:New Zealand / Q000453:epidemiology; D018579:Patient Selection; D012525:Saskatchewan / Q000453:epidemiology; D012720:Severity of Illness Index
chemical_list: D000318:Adrenergic beta-Agonists; D005280:Fenoterol; D000420:Albuterol